메뉴 건너뛰기




Volumn 45, Issue 1, 2013, Pages 40-47

Feasibility of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer

Author keywords

Fluorouracil; Leucovorin; Ovarian neoplasms; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

EID: 84879079933     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.45.1.40     Document Type: Article
Times cited : (16)

References (21)
  • 1
    • 84863275781 scopus 로고    scopus 로고
    • Major clinical research advances in gynecologic cancer in 2011
    • Suh DH, Kim K, Kim JW. Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol. 2012;23:53-64.
    • (2012) J Gynecol Oncol. , vol.23 , pp. 53-64
    • Suh, D.H.1    Kim, K.2    Kim, J.W.3
  • 2
    • 0141688377 scopus 로고    scopus 로고
    • Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    • Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-200.
    • (2003) J Clin Oncol. , vol.21 , pp. 3194-3200
    • Ozols, R.F.1    Bundy, B.N.2    Greer, B.E.3    Fowler, J.M.4    Clarke-Pearson, D.5    Burger, R.A.6
  • 3
    • 77950354955 scopus 로고    scopus 로고
    • Markman M. Optimal management of recurrent ovarian cancer. Int J Gynecol Cancer. 2009;19 Suppl 2:S40-3.
  • 4
    • 84863259260 scopus 로고    scopus 로고
    • Recent advances in the biomarkers for epithelial ovarian cancer
    • Kim YH, Kim SC. Recent advances in the biomarkers for epithelial ovarian cancer. J Gynecol Oncol. 2011;22:219-21.
    • (2011) J Gynecol Oncol. , vol.22 , pp. 219-221
    • Kim, Y.H.1    Kim, S.C.2
  • 5
    • 0031741679 scopus 로고    scopus 로고
    • Oxaliplatin: a review of preclinical and clinical studies
    • Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053-71.
    • (1998) Ann Oncol. , vol.9 , pp. 1053-1071
    • Raymond, E.1    Chaney, S.G.2    Taamma, A.3    Cvitkovic, E.4
  • 6
    • 0000460127 scopus 로고    scopus 로고
    • Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
    • Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855-65.
    • (1996) Biochem Pharmacol. , vol.52 , pp. 1855-1865
    • Rixe, O.1    Ortuzar, W.2    Alvarez, M.3    Parker, R.4    Reed, E.5    Paull, K.6
  • 7
    • 0342398241 scopus 로고    scopus 로고
    • Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin
    • Prefontaine M, Donovan JT, Powell JL, Buley L. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Gynecol Oncol. 1996;61:249-52.
    • (1996) Gynecol Oncol. , vol.61 , pp. 249-252
    • Prefontaine, M.1    Donovan, J.T.2    Powell, J.L.3    Buley, L.4
  • 9
    • 0030722949 scopus 로고    scopus 로고
    • Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
    • Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs. 1997;8:876-85.
    • (1997) Anticancer Drugs. , vol.8 , pp. 876-885
    • Raymond, E.1    Buquet-Fagot, C.2    Djelloul, S.3    Mester, J.4    Cvitkovic, E.5    Allain, P.6
  • 10
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
    • (2004) J Clin Oncol. , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3    Fuchs, C.S.4    Ramanathan, R.K.5    Williamson, S.K.6
  • 11
    • 0038157032 scopus 로고    scopus 로고
    • Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study
    • Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol. 2003;14:537-42.
    • (2003) Ann Oncol. , vol.14 , pp. 537-542
    • Pectasides, D.1    Pectasides, M.2    Farmakis, D.3    Bountouroglou, N.4    Nikolaou, M.5    Koumpou, M.6
  • 12
    • 3543147160 scopus 로고    scopus 로고
    • Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy
    • Sundar S, Symonds RP, Decatris MP, Kumar DM, Osman A, Vasanthan S, et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol. 2004;94:502-8.
    • (2004) Gynecol Oncol. , vol.94 , pp. 502-508
    • Sundar, S.1    Symonds, R.P.2    Decatris, M.P.3    Kumar, D.M.4    Osman, A.5    Vasanthan, S.6
  • 13
    • 4644254283 scopus 로고    scopus 로고
    • Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study
    • Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol. 2004;95:165-72.
    • (2004) Gynecol Oncol. , vol.95 , pp. 165-172
    • Pectasides, D.1    Pectasides, M.2    Farmakis, D.3    Gaglia, A.4    Koumarianou, A.5    Nikolaou, M.6
  • 14
    • 51449084510 scopus 로고    scopus 로고
    • Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma
    • Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, et al. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet. 2008;278:457-62.
    • (2008) Arch Gynecol Obstet. , vol.278 , pp. 457-462
    • Rosa, D.D.1    Awada, A.2    Mano, M.S.3    Selleslags, J.4    Lebrun, F.5    Gil, T.6
  • 17
    • 84879071941 scopus 로고    scopus 로고
    • Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0 [Internet]. Bethesda: National Cancer Institute, [cited 2012 Nov 1]. Available from
    • Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0 [Internet]. Bethesda: National Cancer Institute; 2003 [cited 2012 Nov 1]. Available from: http://ctep.cancer. gov/forms/CTCAEv3.pdf.
    • (2003)
  • 18
    • 0024407292 scopus 로고
    • Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
    • Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989;43: 237-50.
    • (1989) Biomed Pharmacother. , vol.43 , pp. 237-250
    • Mathe, G.1    Kidani, Y.2    Segiguchi, M.3    Eriguchi, M.4    Fredj, G.5    Peytavin, G.6
  • 19
    • 0036299552 scopus 로고    scopus 로고
    • Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/-taxane-pretreated ovarian cancer patients
    • Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/-taxane-pretreated ovarian cancer patients. Ann Oncol. 2002;13:258-66.
    • (2002) Ann Oncol. , vol.13 , pp. 258-266
    • Dieras, V.1    Bougnoux, P.2    Petit, T.3    Chollet, P.4    Beuzeboc, P.5    Borel, C.6
  • 20
    • 0030480745 scopus 로고    scopus 로고
    • Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
    • Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol. 1996;7:1065-70.
    • (1996) Ann Oncol. , vol.7 , pp. 1065-1070
    • Chollet, P.1    Bensmaine, M.A.2    Brienza, S.3    Deloche, C.4    Cure, H.5    Caillet, H.6
  • 21
    • 0029023692 scopus 로고
    • Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels
    • Morgan RJ Jr, Speyer J, Doroshow JH, Margolin K, Raschko J, Sorich J, et al. Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol. 1995;58:79-85.
    • (1995) Gynecol Oncol. , vol.58 , pp. 79-85
    • Morgan Jr, R.J.1    Speyer, J.2    Doroshow, J.H.3    Margolin, K.4    Raschko, J.5    Sorich, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.